CN1522143A - 辅酶q与二十碳五烯酸(epa) - Google Patents
辅酶q与二十碳五烯酸(epa) Download PDFInfo
- Publication number
- CN1522143A CN1522143A CNA028110110A CN02811011A CN1522143A CN 1522143 A CN1522143 A CN 1522143A CN A028110110 A CNA028110110 A CN A028110110A CN 02811011 A CN02811011 A CN 02811011A CN 1522143 A CN1522143 A CN 1522143A
- Authority
- CN
- China
- Prior art keywords
- disease
- type
- preparation
- epa
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title claims abstract description 100
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title claims abstract description 99
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title claims abstract description 99
- 229960005135 eicosapentaenoic acid Drugs 0.000 title claims abstract description 99
- 239000005515 coenzyme Substances 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 54
- 229930195729 fatty acid Natural products 0.000 claims abstract description 54
- 239000000194 fatty acid Substances 0.000 claims abstract description 54
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 54
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 53
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 52
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 51
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229940035936 ubiquinone Drugs 0.000 claims abstract description 51
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 21
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 17
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 17
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 17
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 11
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims abstract description 9
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims abstract description 8
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims abstract description 8
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims abstract description 8
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims abstract description 7
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002733 gamolenic acid Drugs 0.000 claims abstract description 7
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 5
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 19
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 230000003203 everyday effect Effects 0.000 claims description 15
- 208000028017 Psychotic disease Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 208000007101 Muscle Cramp Diseases 0.000 claims description 11
- 208000005392 Spasm Diseases 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 125000004494 ethyl ester group Chemical group 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 6
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 6
- 206010061216 Infarction Diseases 0.000 claims description 5
- 208000028484 Urethral disease Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 claims description 5
- 208000016097 disease of metabolism Diseases 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 210000004994 reproductive system Anatomy 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010002027 Amyotrophy Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 102000006311 Cyclin D1 Human genes 0.000 claims description 4
- 108010058546 Cyclin D1 Proteins 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims description 4
- 206010026749 Mania Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000034189 Sclerosis Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 201000007930 alcohol dependence Diseases 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 208000015202 calcium metabolic disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 210000003405 ileum Anatomy 0.000 claims description 4
- 230000007574 infarction Effects 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000027758 ovulation cycle Effects 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 210000002027 skeletal muscle Anatomy 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 210000003708 urethra Anatomy 0.000 claims description 4
- 206010005052 Bladder irritation Diseases 0.000 claims description 3
- 206010006298 Breast pain Diseases 0.000 claims description 3
- 206010007027 Calculus urinary Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 208000006662 Mastodynia Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 230000003821 menstrual periods Effects 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000008281 urolithiasis Diseases 0.000 claims description 3
- 210000001215 vagina Anatomy 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 229940079920 digestives acid preparations Drugs 0.000 claims description 2
- 229910003002 lithium salt Inorganic materials 0.000 claims description 2
- 159000000002 lithium salts Chemical class 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 abstract description 3
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 abstract description 2
- 238000011260 co-administration Methods 0.000 abstract 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 1
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- 230000033764 rhythmic process Effects 0.000 description 11
- 241001597008 Nomeidae Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 229940125532 enzyme inhibitor Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- -1 18:3n-6) Chemical compound 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000029522 neoplastic syndrome Diseases 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101710153103 Long-chain-fatty-acid-CoA ligase FadD13 Proteins 0.000 description 1
- 101710153099 Long-chain-fatty-acid-CoA ligase FadD15 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710154693 Medium/long-chain-fatty-acid-CoA ligase FadD17 Proteins 0.000 description 1
- 101710141422 Medium/long-chain-fatty-acid-CoA/3-oxocholest-4-en-26-oate-CoA ligase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001195 polyisoprene Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
Abstract
泛醌(辅酶Q)与二十碳五烯酸的联合给药,其可用一或多种不饱和脂肪酸γ-亚麻酸、二高-γ-亚麻酸、花生四烯酸以及十八碳四烯酸补充或代替。脂肪酸二十二碳六烯酸以及亚油酸含量应少于10%。
Description
二十碳五烯酸(EPA,20:5n-3)是一种高度不饱和脂肪酸,对许多疾病有治疗作用。例如,因为它能降低甘油三酯水平,产生血管舒张作用并具有抗心率失常的效果,因此可用于心血管疾病。它在多种疾病中具有消炎效果,如类风湿性关节炎、骨关节炎以及炎性肠疾病。它对精神性以及神经性失调具有有益的效果,如精神分裂症、抑郁症以及亨延顿氏疾病。它具有抗癌症效果,特别在减轻癌症恶病质(cancer cachexia)方面具有效果。
通常EPA异常地安全,除了轻度胃肠道失调以外没有很要紧的副作用。美国食品与药品管理局(FDA)已经确定,当存在于鱼油中剂量多达3g/天,对大众而言,EPA通常仍被认为是安全的(GRAS)。
尽管二十碳五烯酸通常以鱼或其他海洋生物油或以混合乙基酯的形式进行给药,其中其与许多其他脂肪酸包括二十二碳六烯酸(DHA)进行混合,本申请者及合作者最近发现制备的二十碳五烯酸或其衍生物制剂的纯度越高,其治疗效果显著增强。特别有效的制剂是那些其中二十二碳六烯酸或其衍生物含量低或非常低或没有的制剂(WO00/44361)。特别有价值的制剂是其中二十碳五烯酸水平高于90%或优选高于95%以及其中二十二碳六烯酸含量低于5%,以及优选低于1%的制剂。亚油酸会影响二十碳五烯酸的作用,因此当制剂中亚油酸含量低于5%以及优选低于1%也很有意义。
本发明解决了当EPA以高剂量以及提纯形式使用的时候的迄今为止还不为人所知的可能的副作用,并提供了一种减轻这种副作用的方法。本发明不仅发现了EPA的应用,而且还包括其他有治疗意义的基本脂肪酸的应用,尤其是二十碳五烯酸前体,十八碳四烯酸(stearidonic acid,18:4n-3)以及ω-6脂肪酸γ-亚麻酸(gamma-linolenic acid,18:3n-6)、二高-γ-亚麻酸(dihomo-gamma-linolenic acid,20:3n-6)以及花生四烯酸(20:4n-6)。
不饱和基本脂肪酸(EFAs)的代谢途径显示在图1中。EFAs与维生素类似,是人和动物代谢所必需的,但是不能由哺乳动物体内合成。有两类EFAs:n-6(或ω-6)以及n-3(或ω-3)。n-6系列亚油酸(LA)以及n-3系列的α-亚麻酸(ALA)母体化合物是食物中发现的主要化合物。但是,要对人体有用,这些母体化合物必需转化成图1中显示的所谓的衍生基本脂肪酸。这些衍生的EFAs在所有的细胞内膜和细胞外膜的结构中发挥重要作用。它们也在许多不同类型的细胞激活后从这些细胞膜中释放出来,所述的细胞激活将磷脂酶A2、C以及D转化成活化形式并直接或间接地导致游离酸从磷脂膜中释放出来。
本发明提供了泛醌(辅酶Q)与EPA的联合给药。通过将泛醌与EPA掺入到制剂中可以极其方便地实现。本发明提供了药用或营养用途的制剂,所述制剂包含二十碳五烯酸(EPA)以及任何合适的可吸收形式的泛醌。
这些制剂明确地不含任何形式的抗坏血酸或抗坏血酸盐,本发明者发现后者将使二十碳五烯酸制剂不稳定。此外,本制剂不包含任何其他的降三甘油酯药物,如潘特生,因为当使用提纯的二十碳五烯酸的时候,所述药物的甘油酯下降效果也许会不适当地变大。不饱和酸本身有降低三甘油酯效果。此外,本发明不涉及下列制剂,其中脂肪酸制剂以相同的剂量或同样的包装与下列酶抑制剂进行的组合制剂,酶抑制剂选自COX-1和/或COX-2抑制剂、LOX抑制剂以及一或多种FACL酶抑制剂。
本发明也提供了泛醌(辅酶Q)以及EPA在制备治疗患者疾病的药物中的用途,所述疾病为常规用EPA治疗的任何失调,并且本发明还提供了一种通过联合施用泛醌(辅酶Q)以及EPA治疗或预防所述失调的方法。所述失调包括心血管以及脑血管疾病;炎症在其中发挥作用的疾病,包括类风湿关节炎以及骨关节炎、炎性肠失调、子宫内膜异位以及哮喘;异常和疼痛性肌肉痉挛性失调,包括过敏性肠或膀胱综合征、痛经或骨骼肌痉挛(spasms);中枢以及外周神经系统机能失调,包括精神性以及神经失调;癌症以及癌症相关综合征,包括恶病质。
优选地,EPA与泛醌的比例介于2000∶1和1∶1之间,以及更优选介于200∶1和3∶1之间。
EPA可为游离酸、钠、钾、锂或其他盐、任何酯的形式,包括乙基酯或胆固醇酯、酰胺、磷脂或三-、二-或单甘油酯。也可使用可增加血液或组织中脂肪酸水平的其他衍生物。优选的EPA形式为乙基酯或三甘油酯。这些形式特别为胃肠道良好地耐受。
二十碳五烯酸或衍生物应该具有一定的纯度水平,这样可以降低其他脂肪酸或脂肪酸衍生物对生物作用关键点的干扰作用。在本发明制剂的二十碳五烯酸制剂中二十碳五烯酸或衍生物应该至少为70%的纯度以及优选至少80%的纯度。特别优选二十碳五烯酸或衍生物为90%或95%的纯度。特别地,通常在油中发现以及并干扰脂肪酸治疗作用的两种基本脂肪酸:二十二碳六烯酸以及亚油酸。必要的条件是用于本发明制剂的任何脂肪酸或脂肪酸衍生物制剂中,二十二碳六烯酸或衍生物以及亚油酸或衍生物存在的量各少于10%,优选少于5%以及特别优选少于1%。
有利的是EPA每日剂量介于100mg和100g之间,并且泛醌每日剂量介于10mg和2000mg之间。优选地,EPA每日剂量介于0.5g和20g之间,并且泛醌的每日剂量介于50mg和500mg之间。
本发明制剂优选地制备成适合口服给药或经肠给药。其也可制备成适合局部、阴道或直肠给药,或适合通过静脉内、肌内或皮下途径进行肠胃外给药。
尽管当使用非常高剂量的EPA的时候,这种联合给药可能特别有价值,任何剂量的EPA也有用于降低任何副作用以及也有助于保护EPA抵抗体内氧化的风险。
泛醌,也为辅酶Q,是一种在人体大多数细胞中可以发现的分子(LErnster & G Dallner,Biochimica Biophysica Acta 1995;1271:195-204)。其结构为:
泛醌50
该分子由苯醌环和聚异戊二烯侧链组成。侧链中异戊二烯单元是可变的,但每一物种具有特定的数字,人类中为10。泛醌在机体中有两种主要的明确作用。首先它是线粒体中呼吸链的成分,是正常电子传递以及正常能量产生所必须的。其次,它具有很强的抗氧化特性,并因此可有助于预防从高度不饱和脂肪酸如EPA产生潜在有害的自由基。
其他的高度不饱和脂肪酸也可用于治疗,可能产生自由基,理论上可能带来副作用。所述脂肪酸尤其包括ω-6脂肪酸,γ-亚麻酸、二高-γ-亚麻酸以及花生四烯酸,以及二十碳五烯酸前体,十八碳四烯酸。
本发明另一方面提供了这些脂肪酸或衍生物的制剂,其包含辅酶Q,以及涉及联合施用辅酶Q以及上述的任何脂肪酸或衍生物治疗或预防失调的方法。在任何的本发明上述制剂中的EPA可用一种或多种高度不饱和脂肪酸补充或替代,所述的脂肪酸选自γ-亚麻酸、二高-γ-亚麻酸、花生四烯酸以及十八碳四烯酸。当用EPA的时候,用于制备本发明制剂的脂肪酸制剂应该包含多于70%的特定脂肪酸,优选多余80%或90%,以及更优选多余95%。脂肪酸制剂也包含少于10%,优选少于5%以及更优选少于1%的二十二碳六烯酸或亚油酸。
也可有下述情况,其中合适地将一种含70%或更高的一种脂肪酸的制剂与含70%或更高的另一种脂肪酸的制剂进行组合。例如,在下述情况下,合适地将n-3系列的脂肪酸与一种n-6系列进行组合,EPA和/或SA制剂可与GLA和/或DGLA或AA制剂组合,从而制备最终的产物。
EPA以及其他脂肪酸可以任何可吸收形式进行提供,这样将导致在血浆或红细胞膜或制剂直接使用(如对皮肤)的组织中的EPA或其他脂肪酸浓度升高。EPA或其他脂肪酸浓度的这种变化可很方便地用标准技术如用标准脂质萃取后进行的脂质级分的气相色谱进行。在进行气相色谱之前,脂质萃取可任选接着使用薄层色谱或高压液相色谱进行脂质类别的分离。EPA或其他脂肪酸可以游离脂肪酸、盐、酯如乙基酯、酰胺、磷脂,三-、二-或单-甘油酯或以任何其他的可吸收形式进行提供。
EPA或其他脂肪酸的每日剂量可为100mg~100g,但优选在0.5g~20g的范围内。EPA或其他脂肪酸在为所述制剂提供的含EPA物质中的浓度可高于70%的任何浓度,但优选高于80%或90%以及更优选高于95%。
制剂中泛醌的每日剂量可为10mg~2000mg每天,但优选为50mg~500mg每天。EPA或其他脂肪酸与泛醌的比例可为2000∶1~1∶1,但优选为200∶1~3∶1。
EPA/其他脂肪酸制剂以及泛醌可掺入到任何合适的制剂或溶媒中,用于口服给药、经肠给药,通过静脉内、肌内或皮下途径进行肠胃外给药,或通过皮肤进行局部给药或通过栓剂或阴道栓进行直肠或阴道给药。
研究表明应用基本脂肪酸(EFAs),包括二十碳五烯酸,在许多疾病的治疗中具有治疗有益的效果。因此本发明的优点非常广泛。下列给出的研究病例,但基于目前以及未来的有关EFAs应用的有关知识,其应用预期是广泛的。证明这些脂肪酸在许多疾病中具有广泛的用途的已经授权专利实例为下述美国专利:US4,826,877;5,847,000;5,457,130;4,302,447;4,681,896;5,198,468;5,922,345。
本发明所述制剂适于治疗任何形式的癌症以及癌症恶病质,并且本发明进一步提供了这种治疗,以及脂肪酸制剂与泛醌的组合在用于治疗癌症或癌症恶病质的药物的制备方法中的用途。
本发明进一步提供了异常心率以及节律的治疗或控制,以及脂肪酸制剂与泛醌的组合在用于治疗或控制异常心率和节律的药物的制备方法中的用途。
所述制剂也适于治疗任何形式的精神性疾病,包括精神分裂症、分裂情感性失调(schizoaffective disorder)、分裂型精神性疾病(schizotypy)、抑郁症、焦虑症、两极失调(bipolar disorder)、躁狂症、边缘型个性失调(borderlinepersonality disorder)、酒精中毒以及注意力不足极度活跃失调(attention deficitheperactivity disorder)或任何其他的精神性疾病,并且本发明提供了这种治疗以及脂肪酸制剂与泛醌的组合在用于治疗任何一种所述精神性疾病的药物的制备方法中的用途。
所述制剂可用于治疗任何形式的神经或神经退行性疾病,包括帕金森氏疾病、阿尔茨海默氏疾病、肌萎缩外侧硬化症、亨廷顿氏疾病以及其他″三联重复″(triplet-repeat)疾病、中风、多发性梗塞(multi-infarct)以及其他形式的痴呆、多发性硬化症、慢性疲劳以及癫痫症,并且本发明提供了这种治疗以及脂肪酸制剂与泛醌的组合在用于治疗任何一种所述神经或神经退行性疾病的药物的制备方法中的用途。
所述制剂适于治疗任何形式的炎性疾病,包括任何形式的关节炎,任何形式的炎性皮肤疾病,包括牛皮癣以及湿疹、哮喘,任何形式的炎性胃肠道疾病,包括溃疡性结肠炎以及局限性回肠病,以及任何其他的器官包括肾、生殖系统、眼以及脑的任何炎性疾病,并且本发明提供了这种治疗以及脂肪酸制剂与泛醌的组合在用于治疗任何一种所述炎性疾病的药物的制备方法中的用途。
所述制剂可用于治疗任何形式的心血管或脑血管疾病,并且本发明提供了这种治疗以及脂肪酸制剂与泛醌组合在制备用于治疗任何心血管或脑血管疾病的药物的方法中的用途。
所述制剂可用于治疗任何形式的呼吸疾病,包括哮喘或慢性阻塞性肺部疾病,并且本发明提供了这种治疗以及脂肪酸制剂与泛醌的组合在用于治疗任何呼吸疾病,包括哮喘或慢性阻塞性肺部疾病的药物的制备方法中的用途。
所述制剂可用于治疗任何形式的代谢疾病,包括糖尿病、综合征X、以及任何钙代谢紊乱包括骨质疏松症、尿石病、或尿道结石形成,并且本发明提供了所述的治疗以及脂肪酸制剂与泛醌的组合在制备用于治疗任何一种所述代谢疾病药物的方法中的用途。
所述制剂可用于治疗任何形式的肾或尿道疾病,并且本发明提供了所述治疗以及脂肪酸制剂与泛醌的组合在制备用于治疗任何肾或尿道疾病的药物的方法中的用途。
所述制剂可用于治疗任何形式的生殖系统或月经周期疾病或失调,包括乳房疼痛、经期前综合征、痛经或子宫内膜异位,并且本发明提供所述治疗以及脂肪酸制剂与泛醌的组合在用于治疗所述生殖系统或月经周期疾病或失调,包括乳房疼痛、经期前综合征、痛经或子宫内膜异位的药物的制备方法中的用途。
所述制剂可用于治疗任何形式的以异常和疼痛性肌肉痉挛为特征疾病或的失调,包括过敏性肠(irritable bowel)或膀胱综合征或骨骼肌痉挛,并且本发明提供了这种治疗和脂肪酸制剂与泛醌的组合在用于治疗以异常和疼痛性肌肉痉挛为特征的疾病,包括过敏性肠或膀胱综合征或骨骼肌痉挛药物的制备方法中的用途。
二十碳五烯酸被认为是具有抗癌潜力的脂肪酸。S S Palakurthi等(癌症研究2000;60:2919-25)报道了EPA能抑制癌症细胞的生长并报道了描述了类似的发现的在前文献。然而无论是Palakurthi等人,还是在前文献都没有提供任何关于如何将这些实验发现转化成用于人癌症治疗的信息。授权欧洲专利(EPO464084)描述了EPA在治疗癌症关联的体重减轻中的用途,但是没有讨论EPA用于治疗潜在癌症本身的可能性。
下列实施例报道了已患癌症个体以1g/天的常规剂量服用乙基-EPA的情况。该个体在过去的3年内也同时按2g/天的剂量服用EPA,但是癌症仍然发展。因此可以总结出2g/天或更低剂量的EPA可能在癌症控制方面无效。但是,当EPA的剂量增加到10g/天,在一定的时间内,癌症大小显著减小。这因此表明EPA本身的10g/天剂量具有直接的抗癌症效果。3g/天~30g/天的剂量,以及优选5g/天或20g/天的剂量因此将可用于癌症治疗。EPA可以任何可吸收形式进行提供。但是,三甘油酯形式以及乙基-酯形式对胃肠道相对地无刺激作用,因此为这种大剂量经口给药的优选形式,尽管其他形式可用于静脉内给药途径。口服给药的EPA应该为尽可能的纯净形式,至少70%纯度,优选80-90%纯度,以及更优选95%或更纯。二十二碳六烯酸以及亚油酸各自应该少于5%以及优选少于1%。EPA可配制成胶囊、液体或乳剂,为合适地用于或静脉内给药所必须的形式。
实施例中也描述了当施用高剂量EPA的时候,会有心律不齐的情况,心律不齐可通过联合使用辅酶Q得到成功的控制。但是当施用高剂量的EPA的时候,所述的心律不齐并不是总是出现,因此我们要求保护EPA本身以3g/天或更高的高剂量给药用于癌症治疗的用途。
实施例
一位61岁男性病人,按1g/天的剂量服用二十碳五烯酸乙酯,作为发展非Hodgkin氏淋巴瘤形式的普通健康原因的补充剂,该疾病也称为包膜细胞淋巴瘤。该疾病的特征为称为细胞周期蛋白D1的细胞周期控制因子的过表达。细胞周期蛋白D1似乎使细胞不断地分裂。已有报道称在体外以及在癌症动物模型中,EPA能抑制细胞周期蛋白D1的合成(S S Palakurthi等,癌症研究2000;60:2919-25)。但是,需要高剂量才能在癌症组织中得到所需要的水平。
因此决定给病人按10g/天服用96%纯度的二十碳五烯酸乙酯,含少于1%二十二碳六烯酸以及不能检测到的亚油酸。在给药的第6天,病人的可触知的肿瘤开始消退,显示出EPA具有有益的作用。在EPA治疗中,在病人身上没有观察到重要的副作用。但是,在第10天,他的心率变得明显地没规律,体现在心率以及节律上:从约60/分的低值到约150/分的高值之间振荡并表现出明显的无规律。
没有确定异常节律的可靠原因。一种可能性是由于EPA的高摄入引起的。非常高剂量的EPA理论上增加氧化的代谢物,后者会扰乱心脏节律。低剂量的EPA似乎具有强的抗心律不齐的作用,已知许多抗心律不齐药在一定的剂量的时候具有诱导心律不齐(pro-arrhythmic)的作用。
泛醌对心脏节律有有利的效果(RBSingh等,心血管药物及治疗1998;12:347-353)。按120mg/天对服用高剂量EPA的病人进行给药。在第二天心律以及节律恢复到正常,节律均匀以及休息时的心率振荡范围为65-75/分。然后10天后终止泛醌。4天后,心率以及节律波动又恢复了。再服用泛醌,又恢复到正常的心率以及节律。病人因此继续服用泛醌以及高剂量的EPA,在四个月的时间内没有出现心律以及节律异常的反弹。
制剂实施例
1.含500mg乙基酯形式的EPA的软或硬明胶胶囊,其中乙基-EPA的纯度高于90%以及其中二十二碳六烯酸以及亚油酸各自低于5%以及在其中加入30mg泛醌。每天服用1~30粒这种胶囊。
2. 95%纯度的乙基-EPA液体,其中DHA以及亚油酸各自少于1%,调味使之可口,每克含50mg泛醌。每天口服0.5g~20g。
3.微胶囊的(Micro-encapsulated)80%纯度的乙基-EPA,其中DHA少于10%,含100mg泛醌/g。每天服用提供100mg~20g EPA的所述制剂。
4.如实施例1-3中的制剂,但EPA以游离酸、钠盐、锂盐、酰胺、磷脂,单-、二-或三甘油酯的形式,或任何其他的可吸收形式进行提供。
5.如实施例1-4中的制剂,其中EPA以其中包含多于70%的二十碳五烯酸以及其中DHA以及亚油酸含量各少于10%的形式进行提供。
6.如实施例1-5中的制剂,但其中EPA以及泛醌以适合经静脉内、肌内或皮下途径进行的肠胃外给药的制剂形式进行提供。
7.如实施例1-5中的制剂,但其中EPA以及泛醌以适合局部给药的制剂形式提供。
8.如实施例1-7中的制剂,但其中EPA用一或多种选自γ-亚麻酸、二高-γ-亚麻酸、花生四烯酸以及十八碳四烯酸的脂肪酸进行补充或替换。
Claims (30)
1.药用或营养用制剂,自下列组份制备:
二十碳五烯酸(EPA)制剂,含多于70%的EPA和少于10%的二十二碳六烯酸(DHA)以及少于10%的亚油酸;以及
任何合适的可吸收形式的泛醌。
2.根据权利要求1的制剂,其中EPA与泛醌之比介于2000∶1和1∶1之间,并优选介于200∶1和3∶1之间。
3.根据权利要求1或2的制剂,其中EPA为乙基酯形式。
4.根据权利要求3的制剂,其中乙基-EPA制剂的纯度为80%,并优选高于90%或95%,并且其中DHA含量少于5%,并优选少于1%,其中亚油酸含量也少于5%,并优选少于1%。
5.根据权利要求1或2的制剂,其中EPA为游离酸、钠盐、锂盐或其他盐、任何酯、酰胺、磷脂或三-、二-或单甘油酯的形式。
6.权利要求1~5中任何一项的制剂,其中EPA的每日剂量介于100mg和100g之间,并且泛醌的每日剂量介于10mg和2000mg之间。
7.根据权利要求6的制剂,其中EPA的每日剂量介于0.5g和20g之间,并且泛醌的每日剂量介于50mg和500mg之间。
8.权利要求1~7中任何一项的制剂,其中EPA用一种或多种高度不饱和脂肪酸补充或代替,所述的高度不饱和脂肪酸选自γ-亚麻酸、二高-γ-亚麻酸、花生四烯酸以及十八碳四烯酸,并且其中这些脂肪酸制剂含多于70%的相关脂肪酸以及少于10%的DHA和少于10%的亚油酸,并优选多于90%或95%的所述脂肪酸以及少于5%,更优选少于1%的DHA和少于5%,更优选少于1%的亚油酸。
9.权利要求1~8中任何一项的制剂,其中将含EPA或其他脂肪酸的物质与泛醌一起制备成适合口服给药或经肠给药。
10.权利要求1~8中任何一项的制剂,其中将含EPA或其他脂肪酸的物质与泛醌一起配制成适合经局部、阴道或直肠给药。
11.权利要求1~8中任何一项的制剂,其中将含EPA或其他脂肪酸的物质与泛醌一起配制成适合经静脉内、肌内或皮下途径进行经肠胃外给药。
12.权利要求1-11中任何一项的药用制剂用来治疗任何形式的癌症或癌症恶病质。
13.权利要求1-11中任何一项的药用制剂用来治疗任何形式的精神性疾病,所述精神性疾病包括精神分裂症、分裂情感性失调、分裂型精神性疾病、抑郁症、焦虑症、两极失调、躁狂症、边缘型个性失调、酒精中毒以及注意力不足极度活跃失调或任何其他的精神性疾病。
14.权利要求1-11中任何一项的药用制剂用来治疗任何形式的神经或神经退行性疾病,所述疾病包括帕金森氏疾病、阿尔茨海默氏疾病、亨廷顿氏疾病或任何其他的″三联重复″疾病、肌萎缩外侧硬化症、中风、多发性梗塞或任何其他形式的痴呆、多发性硬化症、慢性疲劳以及癫痫症。
15.权利要求1-11中任何一项的药用制剂用来治疗任何形式的炎性疾病,所述疾病包括任何形式的关节炎、任何形式的炎性皮肤疾病,包括牛皮癣以及湿疹、哮喘,任何形式的炎性胃肠道疾病包括溃疡性结肠炎以及局限性回肠病,以及任何其他的器官包括眼和脑的任何炎性疾病。
16.权利要求1-11中任何一项的药用制剂用来治疗任何形式的心血管或脑血管疾病。
17.权利要求1-11中任何一项的药用制剂用来治疗任何形式的呼吸疾病,如哮喘或慢性阻塞性肺部疾病。
18.权利要求1-11中任何一项的药用制剂用来治疗任何形式的代谢疾病,所述疾病包括糖尿病、X综合征,以及任何钙代谢紊乱,包括骨质疏松症、异位钙化或尿道结石形成。
19.权利要求1-11中任何一项的药用制剂用来治疗任何肾或尿道疾病。
20.权利要求1-11中任何一项的药用制剂用来治疗任何形式的生殖系统疾病,包括乳房疼痛、经期前综合征、痛经或子宫内膜异位。
21.权利要求1-11中任何一项的药用制剂用来治疗任何形式的以异常和疼痛性肌肉痉挛为特征的疾病或失调,包括过敏性肠或膀胱综合征或骨骼肌痉挛。
22.权利要求1-11中任何一项所述的脂肪酸制剂与泛醌联合给药用于治疗任何下列疾病或失调:
任何形式的癌症;
任何形式的精神性疾病,包括精神分裂症、分裂情感性失调、分裂型精神性疾病、抑郁症、焦虑症、两极失调、躁狂症、边缘型性格紊乱、酒精中毒以及注意力不足极度活跃失调或任何其他的精神性病;
任何形式的神经或神经退行性疾病,包括帕金森氏疾病、阿尔茨海默氏疾病、亨廷顿氏疾病或任何其他的″三联重复″疾病、肌萎缩外侧硬化症、中风、多发性梗塞或其他形式的痴呆、多发性硬化症、慢性疲劳以及癫痫症;
任何形式的炎性疾病,包括任何形式的关节炎、任何形式的炎性皮肤疾病,包括牛皮癣和湿疹、哮喘,任何形式的炎性胃肠道疾病包括溃疡性结肠炎和局限性回肠病,以及任何其他的器官包括眼和脑的任何炎性疾病;
任何形式的心血管或脑血管疾病;
任何形式的呼吸疾病;
任何形式的代谢疾病,包括糖尿病、X综合征,任何钙代谢紊乱包括骨质疏松症、尿石病或尿道结石形成;
任何形式的肾或尿道疾病;
任何形式的生殖系统或月经周期疾病或失调;
任何以异常和疼痛性肌肉痉挛为特征的疾病或失调。
23.权利要求1-11中任何一项所述的脂肪酸制剂与泛醌在制备用于治疗任何一种下述疾病或失调的药物中的用途:
任何形式的癌症;
任何形式的精神性疾病,包括精神分裂症、分裂情感性失调、分裂型精神性疾病、抑郁症、焦虑症、两极失调、躁狂症、边缘型个性失调、酒精中毒以及注意力不足极度活跃失调或任何其他的精神性疾病;
任何形式的神经或神经退行性疾病,包括帕金森氏疾病、阿尔茨海默氏疾病、亨廷顿氏疾病或任何其他的″三联重复″疾病、肌萎缩外侧硬化症、中风、多发性梗塞或其他形式的痴呆、多发性硬化症、慢性疲劳以及癫痫症;
任何形式的炎性疾病,包括任何形式的关节炎、任何形式的炎性皮肤疾病,包括牛皮癣以及湿疹、哮喘,任何形式的炎性胃肠道疾病,包括溃疡性结肠炎以及局限性回肠病,以及任何其他的器官包括眼和脑的任何炎性疾病;
任何形式的心血管或脑血管疾病;
任何形式的呼吸疾病;
任何形式的代谢疾病,包括糖尿病、X综合征,以及任何钙代谢紊乱,包括骨质疏松症、尿石病,或尿道结石形成;
任何形式的肾或尿道疾病;
任何形式的生殖系统或月经周期疾病或失调;
任何以异常和疼痛性肌肉痉挛为特征的疾病或失调。
24.一种治疗癌症或制备用于治疗癌症的药物的方法,所述方法涉及施用多于3g/天的二十碳五烯酸制剂,所述制剂为权利要求1制剂的任何合适的可吸收形式。
25.根据权利要求24的方法,其中EPA为乙基酯或三甘油酯的形式。
26.根据权利要求24或25的方法,其中用于制备药物的EPA制剂纯度高于80%以及优选高于90%或95%的纯度,并且DHA水平低于5%以及优选低于1%,以及亚油酸水平低于5%以及优选低于1%。
27.根据权利要求24~26的方法,其中EPA适于口服给药。
28.根据权利要求24~26的方法,其中EPA适于静脉内给药。
29.根据权利要求24~26的方法,其中EPA适于经肠给药。
30.根据权利要求24~26的方法,其中治疗的癌症过量表达细胞周期蛋白D1。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0113104A GB0113104D0 (en) | 2001-05-30 | 2001-05-30 | Coenzyme Q and EPA |
GB0113104.4 | 2001-05-30 | ||
GB0123446A GB0123446D0 (en) | 2001-09-28 | 2001-09-28 | Coenzyme Q and EPA |
GB0123446.7 | 2001-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1522143A true CN1522143A (zh) | 2004-08-18 |
CN1268328C CN1268328C (zh) | 2006-08-09 |
Family
ID=26246133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028110110A Expired - Fee Related CN1268328C (zh) | 2001-05-30 | 2002-05-09 | 辅酶q与二十碳五烯酸(epa) |
Country Status (25)
Country | Link |
---|---|
US (1) | US20020198177A1 (zh) |
EP (1) | EP1390025B1 (zh) |
JP (1) | JP2004531568A (zh) |
KR (1) | KR20040004652A (zh) |
CN (1) | CN1268328C (zh) |
AT (1) | ATE291910T1 (zh) |
BR (1) | BR0209749A (zh) |
CA (1) | CA2449199A1 (zh) |
CZ (1) | CZ299784B6 (zh) |
DE (1) | DE60203494T2 (zh) |
EE (1) | EE200300599A (zh) |
ES (1) | ES2238568T3 (zh) |
HK (1) | HK1058883A1 (zh) |
HR (1) | HRP20030988A2 (zh) |
HU (1) | HUP0401343A3 (zh) |
IL (2) | IL159038A0 (zh) |
IS (1) | IS7005A (zh) |
MX (1) | MXPA03010888A (zh) |
NO (1) | NO20035281L (zh) |
NZ (1) | NZ529339A (zh) |
PL (1) | PL364093A1 (zh) |
PT (1) | PT1390025E (zh) |
RU (1) | RU2003133142A (zh) |
SK (1) | SK14502003A3 (zh) |
WO (1) | WO2002096408A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319534C (zh) * | 2004-10-28 | 2007-06-06 | 昆明翔昊科技有限公司 | 含番茄红素和辅酶q10的制剂及其制备方法 |
CN104994911A (zh) * | 2012-09-06 | 2015-10-21 | 尊贵科学有限公司 | 包括二十碳五烯酸游离酸和γ-亚麻酸游离酸的化妆品组合物及其制造和使用方法 |
CN115776884A (zh) * | 2020-07-09 | 2023-03-10 | 帝斯曼知识产权资产管理有限公司 | 增加肠道微生物群系中的戴阿利斯特杆菌属种的群体的方法 |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
JP4859314B2 (ja) * | 2001-09-26 | 2012-01-25 | 株式会社カネカ | 潰瘍性大腸炎および/又はクローン病治療剤 |
NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US6974592B2 (en) | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
DE60332958D1 (de) | 2002-11-04 | 2010-07-22 | Ocean Nutrition Canada Ltd | Mikrokapseln mit mehrfachen hüllen und verfahren zu deren herstellung |
CN1294825C (zh) * | 2003-03-25 | 2007-01-17 | 汕头市金园区丹味食品发展中心 | 一种营养粉及其制备方法 |
GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
CH698539A8 (de) | 2003-08-18 | 2009-10-15 | Btg Int Ltd | Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. |
WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
EP1713463A4 (en) * | 2004-01-19 | 2009-03-18 | Martek Biosciences Corp | REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES |
CA2553690C (en) | 2004-01-22 | 2016-05-24 | Sung Lan Hsia | Topical co-enzyme q10 formulations and methods of use |
UA94693C2 (ru) * | 2004-04-16 | 2011-06-10 | Солвей Фармасьютикалс Гмбх | Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, которые страдают сердечно-сосудистым заболеванием |
ES2247939B1 (es) * | 2004-08-19 | 2007-04-01 | Fernando Jose Garcia Fructuoso | Suplemento alimenticio basado en la utilizacion de acidos grasos omega-3 (dha-epa) para el tratamiento del sindrome de fatiga cronica. |
GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
DE602006011127D1 (de) | 2005-01-27 | 2010-01-28 | Ocean Nutrition Canada Ltd | Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür |
GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
US9968120B2 (en) | 2006-05-17 | 2018-05-15 | Dsm Nutritional Products Ag | Homogenized formulations containing microcapsules and methods of making and using thereof |
US7838526B2 (en) * | 2005-08-05 | 2010-11-23 | Esther Baldinger | Method of treating neurological disorders |
GB0604647D0 (en) | 2006-03-08 | 2006-04-19 | Shchepinov Mikhail | Stabilized food supplements and their derivatives |
EP2073819B1 (en) * | 2006-05-02 | 2016-12-28 | University of Miami | Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds |
KR101994513B1 (ko) | 2006-06-05 | 2019-06-28 | 디에스엠 뉴트리셔널 프라덕츠 아게 | 개선된 쉘을 가지는 마이크로캡슐 |
NZ578872A (en) | 2007-01-10 | 2012-07-27 | Ocean Nutrition Canada Ltd | Vegetarian microcapsules |
DK2121576T3 (en) | 2007-02-15 | 2016-02-15 | Ct De Rech Sur Les Biotechnologies Marine | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
US9609884B2 (en) * | 2007-03-15 | 2017-04-04 | Suntory Holdings Limited | Anti-fatigue agent |
WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
DE102007055344A1 (de) | 2007-11-19 | 2009-05-20 | K. D. Pharma Bexbach Gmbh | Neue Verwendung von Omega-3-Fettsäure(n) |
ITMI20080145A1 (it) * | 2008-01-30 | 2009-07-31 | Pharmanutra S R L | Uso di acido eicosapentanoico e/o docosaesanoico in donne con endometriosi |
WO2009099886A1 (en) * | 2008-01-31 | 2009-08-13 | Monsanto Technology Llc | Methods of improving dha deposition and related function and/or development |
WO2009126764A1 (en) | 2008-04-11 | 2009-10-15 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
LT3037089T (lt) | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
SG175993A1 (en) | 2009-05-11 | 2011-12-29 | Berg Biosystems Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101106166B1 (ko) * | 2009-06-25 | 2012-01-20 | (주)카이센 | 터널 라이닝 내공변위 측정 장치 |
KR101798670B1 (ko) * | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
US10052299B2 (en) * | 2009-10-30 | 2018-08-21 | Retrotope, Inc. | Alleviating oxidative stress disorders with PUFA derivatives |
RU2728825C2 (ru) * | 2010-03-04 | 2020-07-31 | Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания |
US8178707B2 (en) | 2010-03-25 | 2012-05-15 | Jost Chemical Company | Co-precipitated salts of fatty acids |
DE102010050570A1 (de) * | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
CN102533799A (zh) * | 2010-12-24 | 2012-07-04 | 上海市农业科学院 | 一种源于阴沟肠杆菌的泛醌辅酶q10合成酶基因及其制备方法 |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
RU2458687C1 (ru) * | 2011-03-21 | 2012-08-20 | Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) | Способ коррекции липопероксидации при гиполипидемической терапии пациентов с метаболическим синдромом |
US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
WO2012138765A1 (en) | 2011-04-04 | 2012-10-11 | Berg Pharma Llc | Methods of treating central nervous system tumors |
KR102111997B1 (ko) | 2011-04-26 | 2020-05-18 | 레트로토프 인코포레이티드 | Pufa와 관련된 신경퇴행성 질환 및 근육 질환 |
AU2012249918B2 (en) | 2011-04-26 | 2017-06-15 | Biojiva Llc | Impaired energy processing disorders and mitochondrial deficiency |
EP2701698B1 (en) | 2011-04-26 | 2020-12-23 | Retrotope, Inc. | Disorders implicating pufa oxidation |
DK2701697T3 (da) | 2011-04-26 | 2020-06-29 | Retrotope Inc | Oxidative nethindesygdomme |
US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2780316B1 (en) * | 2011-11-13 | 2020-04-15 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla and methods of treatment using the same |
ES2417679B1 (es) * | 2011-12-09 | 2014-09-15 | Servicio Andaluz De Salud | Prevención y tratamiento de las lesiones renales asociadas a la litiasis renal de la vía urinaria. |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
SG10201903112WA (en) | 2013-04-08 | 2019-05-30 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150051282A1 (en) * | 2013-08-14 | 2015-02-19 | Amarin Pharmaceuticals Ireland Limited | Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
EA034143B1 (ru) | 2013-09-04 | 2020-01-09 | Берг Ллк | Способы лечения рака непрерывной инфузией кофермента q10 |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US9138453B2 (en) | 2013-10-14 | 2015-09-22 | Biomarker Pharmaceuticals, Inc. | Nutrient combinations for affecting an aging process |
US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
AU2013404985B2 (en) | 2013-11-05 | 2017-06-15 | Hill's Pet Nutrition, Inc. | Methods and compositions for improving kidney function |
WO2015185698A1 (en) | 2014-06-04 | 2015-12-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and use of same |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
RU2554806C1 (ru) * | 2014-07-29 | 2015-06-27 | государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) | Способ коррекции повышенного уровня тревоги и депрессии у пациентов с артериальной гипертонией на фоне сахарного диабета 2 типа |
CN113896628A (zh) | 2015-05-13 | 2022-01-07 | Ds生物制药有限公司 | 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法 |
WO2017013492A1 (en) | 2015-07-21 | 2017-01-26 | Dignity Sciences Limited | Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease |
WO2017091279A1 (en) | 2015-11-23 | 2017-06-01 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
KR20190118556A (ko) * | 2016-12-23 | 2019-10-18 | 바스프 에이에스 | 악액질의 예방 및/또는 치료용 오메가-3 지방산 조성물 |
CN110769818A (zh) | 2017-05-17 | 2020-02-07 | 博格有限责任公司 | 辅酶q10制剂在治疗和预防大疱性表皮松解症中的用途 |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
CN110785166A (zh) * | 2017-06-12 | 2020-02-11 | 宫田升平 | 抗癌药及其用途 |
CN111971041A (zh) | 2018-02-07 | 2020-11-20 | Scf制药股份有限公司 | 多不饱和脂肪酸单甘油酯、组合物、方法及其用途 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
AU2019264159A1 (en) | 2018-05-03 | 2020-12-24 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
WO2021168311A1 (en) | 2020-02-21 | 2021-08-26 | Retrotope, Inc. | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
US11491130B2 (en) * | 2021-02-05 | 2022-11-08 | Retrotope, Inc. | Methods of treating amyotrophic lateral sclerosis |
US11510889B2 (en) | 2021-02-05 | 2022-11-29 | Retrotope, Inc. | Methods for inhibiting the progression of neurodegenerative diseases |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
WO2023023397A1 (en) * | 2021-08-20 | 2023-02-23 | Retrotope, Inc | Methods for inhibiting the progression of neurodegenerative diseases |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4273763A (en) * | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
US5922345A (en) * | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
CA2052577C (en) * | 1991-10-01 | 2000-01-11 | Michael John Tisdale | Therapeutic uses of eicosapentaenoic acid |
GB9403855D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
IT1304406B1 (it) * | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
-
2002
- 2002-05-09 PT PT02724475T patent/PT1390025E/pt unknown
- 2002-05-09 EE EEP200300599A patent/EE200300599A/xx unknown
- 2002-05-09 BR BR0209749-4A patent/BR0209749A/pt not_active IP Right Cessation
- 2002-05-09 WO PCT/GB2002/002148 patent/WO2002096408A1/en active IP Right Grant
- 2002-05-09 EP EP02724475A patent/EP1390025B1/en not_active Expired - Lifetime
- 2002-05-09 US US10/140,867 patent/US20020198177A1/en not_active Abandoned
- 2002-05-09 RU RU2003133142/15A patent/RU2003133142A/ru not_active Application Discontinuation
- 2002-05-09 HU HU0401343A patent/HUP0401343A3/hu unknown
- 2002-05-09 CA CA002449199A patent/CA2449199A1/en not_active Abandoned
- 2002-05-09 PL PL02364093A patent/PL364093A1/xx not_active Application Discontinuation
- 2002-05-09 JP JP2002592918A patent/JP2004531568A/ja active Pending
- 2002-05-09 ES ES02724475T patent/ES2238568T3/es not_active Expired - Lifetime
- 2002-05-09 SK SK14502003A patent/SK14502003A3/sk not_active Application Discontinuation
- 2002-05-09 IL IL15903802A patent/IL159038A0/xx active IP Right Grant
- 2002-05-09 CN CNB028110110A patent/CN1268328C/zh not_active Expired - Fee Related
- 2002-05-09 DE DE60203494T patent/DE60203494T2/de not_active Expired - Fee Related
- 2002-05-09 KR KR10-2003-7015381A patent/KR20040004652A/ko not_active Application Discontinuation
- 2002-05-09 MX MXPA03010888A patent/MXPA03010888A/es unknown
- 2002-05-09 AT AT02724475T patent/ATE291910T1/de not_active IP Right Cessation
- 2002-05-09 NZ NZ529339A patent/NZ529339A/en unknown
- 2002-05-09 CZ CZ20033196A patent/CZ299784B6/cs not_active IP Right Cessation
-
2003
- 2003-10-30 IS IS7005A patent/IS7005A/is unknown
- 2003-11-24 IL IL159038A patent/IL159038A/en not_active IP Right Cessation
- 2003-11-27 NO NO20035281A patent/NO20035281L/no not_active Application Discontinuation
- 2003-11-27 HR HR20030988A patent/HRP20030988A2/hr not_active Application Discontinuation
-
2004
- 2004-03-11 HK HK04101780A patent/HK1058883A1/xx not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319534C (zh) * | 2004-10-28 | 2007-06-06 | 昆明翔昊科技有限公司 | 含番茄红素和辅酶q10的制剂及其制备方法 |
CN104994911A (zh) * | 2012-09-06 | 2015-10-21 | 尊贵科学有限公司 | 包括二十碳五烯酸游离酸和γ-亚麻酸游离酸的化妆品组合物及其制造和使用方法 |
CN104994911B (zh) * | 2012-09-06 | 2018-11-27 | Af免疫有限公司 | 包括二十碳五烯酸游离酸和γ-亚麻酸游离酸的化妆品组合物及其制造和使用方法 |
CN109157428A (zh) * | 2012-09-06 | 2019-01-08 | Af免疫有限公司 | 包括二十碳五烯酸游离酸和γ-亚麻酸游离酸的化妆品组合物及其制造和使用方法 |
CN115776884A (zh) * | 2020-07-09 | 2023-03-10 | 帝斯曼知识产权资产管理有限公司 | 增加肠道微生物群系中的戴阿利斯特杆菌属种的群体的方法 |
Also Published As
Publication number | Publication date |
---|---|
HK1058883A1 (en) | 2004-06-11 |
HUP0401343A3 (en) | 2008-08-28 |
ES2238568T3 (es) | 2005-09-01 |
MXPA03010888A (es) | 2004-02-27 |
BR0209749A (pt) | 2004-07-27 |
IL159038A0 (en) | 2004-05-12 |
JP2004531568A (ja) | 2004-10-14 |
NZ529339A (en) | 2004-08-27 |
IL159038A (en) | 2007-07-04 |
CZ20033196A3 (cs) | 2004-06-16 |
HRP20030988A2 (en) | 2004-06-30 |
PL364093A1 (en) | 2004-12-13 |
EP1390025B1 (en) | 2005-03-30 |
RU2003133142A (ru) | 2005-04-20 |
CZ299784B6 (cs) | 2008-11-26 |
KR20040004652A (ko) | 2004-01-13 |
WO2002096408A1 (en) | 2002-12-05 |
CA2449199A1 (en) | 2002-12-05 |
SK14502003A3 (en) | 2004-10-05 |
PT1390025E (pt) | 2005-08-31 |
EP1390025A1 (en) | 2004-02-25 |
HUP0401343A2 (hu) | 2004-11-29 |
DE60203494T2 (de) | 2006-02-09 |
NO20035281D0 (no) | 2003-11-27 |
EE200300599A (et) | 2004-02-16 |
IS7005A (is) | 2003-10-30 |
CN1268328C (zh) | 2006-08-09 |
DE60203494D1 (de) | 2005-05-04 |
US20020198177A1 (en) | 2002-12-26 |
NO20035281L (no) | 2003-11-27 |
ATE291910T1 (de) | 2005-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1268328C (zh) | 辅酶q与二十碳五烯酸(epa) | |
CN1198608C (zh) | 含有必需脂肪酸和生物活性二硫化物的治疗和饮食组合物 | |
CN1109543C (zh) | 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂 | |
JP5441287B2 (ja) | 心血管事象を予防するための必須脂肪酸 | |
JP2699083B2 (ja) | リチウム塩含有薬学的組成物 | |
WO1993009772A1 (en) | Drug for hepatic diseases | |
KR20030016306A (ko) | 지방산의 치료용 조합 | |
CN1338929A (zh) | 治疗精神性和神经性疾病的高纯乙基epa及其他epa衍生物 | |
JPH06157303A (ja) | 脂肪酸治療 | |
RU2001110097A (ru) | Терапевтические композиции (ii) | |
JP2023535067A (ja) | ヒトにおける呼吸器疾患の治療及び/又は予防のためのβ-ヒドロキシブチレート及び関連化合物の投与 | |
US20200085774A1 (en) | Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia | |
AU2002255167B2 (en) | Coenzyme Q and eicosapentaenoic acid (EPA) | |
WO2005046668A1 (ja) | 言語障害予防・治療剤 | |
AU2002255167A1 (en) | Coenzyme Q and eicosapentaenoic acid (EPA) | |
MXPA00000793A (en) | Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060809 |